503088983 12/05/2014 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3135588

SUBMISSION TYPE:	BMISSION TYPE:		NEW ASSIGNMENT			
NATURE OF CONVEYANCE:		ASSIGNMENT	ASSIGNMENT			
CONVEYING PARTY D	ΑΤΑ					
		Name		Execution Date		
GHASSAN S. KASSAB				04/05/2013		
WILLIAM COMBS				04/05/2013		
MARK SVENDSEN			04/05/2013			
H. TOBY MARKOWITZ				04/05/2013		
RECEIVING PARTY DA	TA					
Name:	DTHER	APEUTICS, LLC				
Street Address:	6725 W	6725 WEST STONEGATE DRIVE				
City:	ZIONSV	IONSVILLE				
State/Country:	INDIAN	IANA				
Postal Code:	46077					
Application Number:		51620872				
PROPERTY NUMBERS Property Type		Number				
Application Number:		61776655				
PCT Number: US1		JS1335527				
CORRESPONDENCE D	ΑΤΑ					
Fax Number: (714)		714)546-9035				
	(114/040 0000				
Correspondence will b	e sent to	the e-mail address first; if				
Correspondence will b using a fax number, if [e sent to provided	the e-mail address first; if ; if that is unsuccessful, it				
<i>Correspondence will be using a fax number, if </i> Phone:	e sent to provided	the e-mail address first; if				
<i>Correspondence will be using a fax number, if j</i> Phone: Email:	e sent to provided	<i>the e-mail address first; if</i> ; <i>if that is unsuccessful, it</i> 7146415100				
Correspondence will buusing a fax number, if p Phone: Email: Correspondent Name:	e sent to provided	<i>the e-mail address first; if</i> ; <i>if that is unsuccessful, it</i> 7146415100 Patents@Rutan.com	will be sent v			
Correspondence will b	e sent to provided F	<i>the e-mail address first; if</i> ; <i>if that is unsuccessful, it</i> 7146415100 Patents@Rutan.com RUTAN & TUCKER, LLP	will be sent v SUITE 1400			
Correspondence will be using a fax number, if p Phone: Email: Correspondent Name: Address Line 1: Address Line 4:	e sent to provided F	<i>the e-mail address first; if</i> ; <i>if that is unsuccessful, it</i> 7146415100 Patents@Rutan.com RUTAN & TUCKER, LLP S11 ANTON BOULEVARD, S	will be sent v SUITE 1400			
Correspondence will be using a fax number, if p Phone: Email: Correspondent Name: Address Line 1:	e sent to provided F	<i>the e-mail address first; if</i> <i>; if that is unsuccessful, it</i> 7146415100 Patents@Rutan.com RUTAN & TUCKER, LLP S11 ANTON BOULEVARD, S COSTA MESA, CALIFORNI/	will be sent v SUITE 1400 A 92626	ia US Mail.		
Correspondence will be using a fax number, if p Phone: Email: Correspondent Name: Address Line 1: Address Line 4:	e sent to provided F	the e-mail address first; if ; if that is unsuccessful, it 7146415100 Patents@Rutan.com RUTAN & TUCKER, LLP S11 ANTON BOULEVARD, S COSTA MESA, CALIFORNI/ 101672.0205PCT	will be sent v SUITE 1400 A 92626	ia US Mail.		
Correspondence will b using a fax number, if Phone: Email: Correspondent Name: Address Line 1: Address Line 4: ATTORNEY DOCKET NU	e sent to provided F	the e-mail address first; if ; if that is unsuccessful, it 7146415100 Patents@Rutan.com RUTAN & TUCKER, LLP 611 ANTON BOULEVARD, S COSTA MESA, CALIFORNI/ 101672.0205PCT SOPHIA SARWAR, RI	will be sent v SUITE 1400 A 92626	ia US Mail.		

Total Attachments: 6

source=InventorstoDT#page1.tif

503088983

PATENT REEL: 034398 FRAME: 0678

PATENT ASSIGNMENT

This PATENT ASSIGNMENT (the "Assignment") is entered into as of this 5th day of April, 2013 (the "Effective Date") by and among Ghassan S. Kassab, an individual having a principal address at 6725 West Stonegate Drive, Zionsville, Indiana 46077 ("GSK"), William Combs, an individual having a principal address at 3029 Summer Leaf Court, Galena, Ohio 43021 ("WC"), Mark Svendsen, an individual having a principal address at 8145 North Richardt Avenue, Indianapolis, IN 46256 ("MS"), H. Toby Markowitz, an individual having a principal address at 1670 Ridgewood Lane South, Roseville, Minnesota 55113 ("TM"), and DTherapeutics, LLC, a limited liability company having a principal address at 6725 West Stonegate Drive, Zionsville, Indiana 46077 ("DT"). GSK, WC, MS, TM, and DT may be individually referred to herein as a "Party" or collectively referred to herein as the "Parties."

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

1. <u>Assignment of Patents and/or Patent Applications</u>. GSK, WC, MS, and TM hereby irrevocably assign, transfer, and convey to DT all of their respective right, title, and interest in, to, and under the inventions and patent applications and/or patents set forth in <u>EXHIBIT A</u> attached hereto and hereby incorporated by reference herein, including, without limitation, (i) all inventions and improvements disclosed therein, (ii) all letters patent or similar legal protection granted therefor in the United States, its territorial possessions, and in all foreign countries, unions, or regions, (iii) all continuations, divisions, continuations-in-part, substitutions, reissues, renewals, substitutes, and extensions thereof and applications therefor, in the United States and its territorial possessions and in all foreign countries, unions, or regions, and in all foreign countries, unions, or regions and in all foreign countries, unions, or regions, and all patents and patent applications that claim priority to any of the foregoing, and (v) all rights to enforce including, but not limited to, the right to sue and collect damages for any past or future infringements throughout the world (the "Assigned Patents").

2. <u>Filing and Recording Instruments of Transfer</u>. DT, at its sole discretion, shall make all filings with the requisite intellectual property offices in order to confirm, effectuate, or record this Assignment of the Assigned Patents to DT granted herein. DT shall be responsible to file and record any and all documents of conveyance as may be necessary to vest in DT, as a matter of public record, all of the Assigned Patents.

3. <u>Appointment</u>. GSK, WC, MS, and TM hereby constitute and appoint DT, and its successors and assigns, the true and lawful attorney or attorneys in fact of GSK, WC, MS, and TM, with the full power of substitution, for it and in its name and stead or otherwise, to institute and prosecute from time to time, any proceedings at law, in equity, or otherwise, that DT, or its successors or assigns, may reasonably deem proper in order to assert or enforce any claim, right, or title of any kind in and to the Assigned Patents, and to defend and compromise any and all actions, suits, or proceedings, in respect to any of the foregoing, and generally to do any and all such acts and things in relation thereto as DT, or its successors or assigns, shall reasonably deem advisable, including, but not limited to, the execution and delivery of any and all assignments and instruments in furtherance hereof. GSK, WC, MS, and TM declare that the appointment

PATENT REEL: 034398 FRAME: 0680

1

4. <u>Miscellaneous</u>. This Assignment shall be governed, construed, and enforced in accordance with the laws of the State of Indiana, without regard to any state's choice of laws to the contrary. This Assignment shall inure to the benefit of, and be binding upon, the Parties hereto and their respective successors and assigns. This Assignment may be executed in multiple counterparts, each of which shall be deemed an original and together shall constitute one in the same instrument. Facsimile copies of any signature to this Assignment shall be deemed an original signature hereto.

IN WITNESS WHEREOF, the Parties have executed this Assignment as of the Effective Date.

"GSK"

"WC"

GHASSAN S. KASSAB

WILLIAM COMBS

"MS"

"TM"

MARK SVENDSEN

TOBY MARKOWITZ

"DT"

DTHERAPEUTICS, LLC

Ghassan S. Kassab Manager

4. <u>Miscellaneous</u>. This Assignment shall be governed, construed, and enforced in accordance with the laws of the State of Indiana, without regard to any state's choice of laws to the contrary. This Assignment shall inure to the benefit of, and be binding upon, the Parties hereto and their respective successors and assigns. This Assignment may be executed in multiple counterparts, each of which shall be deemed an original and together shall constitute one in the same instrument. Facsimile copies of any signature to this Assignment shall be deemed an original signature hereto.

IN WITNESS WHEREOF, the Parties have executed this Assignment as of the Effective Date.

"GSK"

"WC"

GHASSAN S. KASSAB

WILLIAM COMBS

Min Conta

"MS"

MARK SVENDSEN

"TM"

TOBY MARKOWITZ

"DT"

DTHERAPEUTICS, LLC

Ghassan S. Kassab Manager

4. <u>Miscellaneous</u>. This Assignment shall be governed, construed, and enforced in accordance with the laws of the State of Indiana, without regard to any state's choice of laws to the contrary. This Assignment shall inure to the benefit of, and be binding upon, the Parties hereto and their respective successors and assigns. This Assignment may be executed in multiple counterparts, each of which shall be deemed an original and together shall constitute one in the same instrument. Facsimile copies of any signature to this Assignment shall be deemed an original signature hereto.

IN WITNESS WHEREOF, the Parties have executed this Assignment as of the Effective Date.

"GSK"

"WC"

GHASSAN S. KASSAB

WILLIAM COMBS

"MS"

"TM"

MARK SVENDSEN

TOBY MARKOWITZ

"DT"

DTHERAPEUTICS, LLC

Ghassan S. Kassab Manager

4. <u>Miscellaneous</u>. This Assignment shall be governed, construed, and enforced in accordance with the laws of the State of Indiana, without regard to any state's choice of laws to the contrary. This Assignment shall inure to the benefit of, and be binding upon, the Parties hereto and their respective successors and assigns. This Assignment may be executed in multiple counterparts, each of which shall be deemed an original and together shall constitute one in the same instrument. Facsimile copies of any signature to this Assignment shall be deemed an original signature hereto.

IN WITNESS WHEREOF, the Parties have executed this Assignment as of the Effective Date.

"GSK"

"WC"

"TM"

GHASSAN S. KASSAB

WILLIAM COMBS

"MS"

MARK SVENDSEN

H. TOBY MARKOWITZ

1 a left Mer

"DT"

DTHERAPEUTICS, LLC

Ghassan S. Kassab Manager

EXHIBIT A

Serial No.	Filing Date	Internal Ref. No.
61/620,872	April 5, 2012	R2012-01-US
61/776,655	March 11, 2013	R2012-14-US
PCT/US13/35527	April 5, 2013	R2013-10-PCT
